Nanotechnology for Invivo Targeted siRNA Delivery

Advances in Genetics

Volumn 88, Issue , 2014, Pages 37-69

  Dahlman, James E ^a,b   Kauffman, Kevin J ^a,b   Langer, Robert ^a,b   Anderson, Daniel G ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Drug delivery; Lipid; Lipidoid; MiRNA; Nanoparticle; Nanotechnology; SiRNA

Indexed keywords

LIPID; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; HUMAN; LIVER; NANOTECHNOLOGY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; LIVER; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84910005937     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800148-6.00003-1     Document Type: Chapter

References (98)

1. Aird W. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circulation research 2007, 100:174-190.
2. Aird W.C. Mechanisms of endothelial cell heterogeneity in health and disease. Circulation Research 2006, 98(2):159-162.
3. Akinc A., Goldberg M., Qin J., Dorkin J.R., Gamba-Vitalo C., Maier M., et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Molecular Therapy 2009, 17(5):872-879.
4. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Molecular Therapy 2010, 18(7):1357-1364.
5. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnology 2008, 26(5):561-569.
6. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Research 2008, 68(23):9788-9798.
7. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Reviews 2013, 65(1):36-48.
8. Alnylam RNAi therapeutics using conjugate delivery Platform 2013, Retrieved from:. http://www.alnylam.com/web/wp-content/uploads/2013/10/ALNY-ConjugateUpdate-OTS2013.pdf.
9. Bartlett D.W., Davis M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnology and Bioengineering 2008, 99(4):975-985.
10. Basha G., Novobrantseva T.I., Rosin N., Tam Y.Y.C., Hafez I.M., Wong M.K., et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Molecular Therapy 2011, 19(12):2186-2200.
11. Belliveau N.M., Huft J., Lin P.J., Chen S., Leung A.K., Leaver T.J., et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for invivo delivery of siRNA. Molecular therapy. Nucleic Acids 2012, 1:e37.
12. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W.Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chemical Biology 2006, 2(12):711-719.
13. Butler J.S., Chan A., Charisse K., Costelha S., Fishman S., Concalves P., et al. Preclinical evaluation of RNAi therapeutics for the treatment of ATTR: An update 2014, Retrieved from:. http://www.alnylam.com/web/assets/Preclinical-Evaluation-of-RNAiTx-for-TTR-Poster-ISA2014.pdf.
14. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
15. Chang P.V., Prescher J.a, Sletten E.M., Baskin J.M., Miller I.a, Agard N.J., et al. Copper-free click chemistry in living animals. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(5):1821-1826.
16. Chiang A.C., Massagué J. Molecular basis of metastasis. The New England Journal of Medicine 2008, 359(26):2814-2823.
17. NCT00689065: Safety study of CALAA-01 to treat solid tumor cancers 2008, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT00689065.
18. NCT01148953: Trial to evaluate safety and tolerability of ALN-TTR01 in transthyretin (TTR) amyloidosis 2010, ClinicalTrials.gov.
19. NCT01437059: Trial to evaluate safety and tolerability of ALN-PCS02 in subjects with elevated LDL-cholesterol (LDL-C) 2011, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT01437059.
20. NCT01559077: Trial to evaluate safety, tolerability, and pharmacokinetics of ALN-TTR02 in healthy volunteer subjects 2012, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT01559077.
21. NCT01617967: Trial to evaluate safety and tolerability of ALN-TTR02 in transthyretin (TTR) amyloidosis 2012, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT01617967.
22. NCT01960348: The study of an investigational drug, ALN-TTR02, for the treatment of transthyretin (TTR)-mediated amyloidosis 2013, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT01960348.
23. NCT01872065: Safety and tolerability study of ARC-520 in healthy volunteers 2013, ClinicalTrials.gov, Retrieved from:. http://www.clinicaltrials.gov/show/NCT01872065.
24. NCT02065336: Study of ARC-520 in patients with chronic hepatitis B virus 2014, ClinicalTrials.gov.
25. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. The New England Journal of Medicine 2013, 369(9):819-829.
26. Dahlman J.E., Barnes C., Khan O., Thiriot A., Jhunjunwala S., Shaw T.E., et al. Invivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nature Nanotechnology May 2014, 19:648-655.
27. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.a, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
28. Deleavey G.F., Damha M.J. Designing chemically modified oligonucleotides for targeted gene silencing. Chemistry & Biology 2012, 19(8):937-954.
29. Dohmen C., Fröhlich T., Lächelt U., Röhl I., Vornlocher H.-P., Hadwiger P., et al. Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing. Molecular therapy. Nucleic acids 2012, 1:e7.
30. Dong Y., Love K.T., Dorkin J.R., Sirirungruang S., Zhang Y., Chen D., et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proceedings of the National Academy of Sciences 2014, 111(11):3955-3960.
31. Drickamer K. Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors. Journal of Biological Chemistry 1996, 271(12):6686-6693.
32. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature February 1998, 391:806-811.
33. Fitzgerald K., Frank-Kamenetsky M., Shulga-Morskaya S., Liebow A., Bettencourt B.R., Sutherland J.E., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014, 383(9911):60-68.
34. Fogal V., Zhang L., Krajewski S., Ruoslahti E. Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Research 2008, 68(17):7210-7218.
35. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer 2012, 12(4):298-306.
36. Gilleron J., Querbes W., Zeigerer A., Borodovsky A., Marsico G., Schubert U., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology 2013, 31(7):638-646.
37. Gonzalez H., Hwang S.J., Davis M.E. New class of polymers for the delivery of macromolecular therapeutics. Bioconjugate Chemistry 1999, 10(6):1068-1074.
38. Gray J. Cancer: genomics of metastasis. Nature 2010, 464:989-990.
39. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010, 464(7290):917-921.
40. Hagberg C.E., Mehlem A., Falkevall A., Muhl L., Fam B.C., Ortsäter H., et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012, 490(7420):426-430.
41. Heidel J.D., Liu J.Y.-C., Yen Y., Zhou B., Heale B.S.E., Rossi J.J., et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation invitro and invivo. Clinical cancer research 2007, 13(7):2207-2215.
42. Heidel J.D., Yu Z., Liu J.Y.-C., Rele S.M., Liang Y., Zeidan R.K., et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(14):5715-5721.
43. Herbert S.P., Stainier D.Y.R. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nature Reviews. Molecular Cell Biology 2011, 12(9):551-564.
44. Hermanson G.T. Bioconjugate techniques 1996, Academic Press. 1st ed.
45. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. Journal of Controlled Release 2005, 107(2):276-287.
46. Hilgenbrink A.R., Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. Journal of Pharmaceutical Sciences 2005, 94(10):2135-2146.
47. Jain K., Kesharwani P., Gupta U., Jain N.K. A review of glycosylated carriers for drug delivery. Biomaterials 2012, 33(16):4166-4186.
48. Jain R.K. Barriers to drug delivery in solid tumors. Scientific American 1994, 271:58-65.
49. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
50. Jayaraman M., Ansell S.M., Mui B.L., Tam Y.K., Chen J., Du X., et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing invivo. Angewandte Chemie (International ed. in English) 2012, 51(34):8529-8533.
51. Jeck W.R., Sharpless N.E. Detecting and characterizing circular RNAs. Nature Biotechnology 2014, 32(5):453-461.
52. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nature Materials 2013, 12(11):967-977.
53. Kanasty R.L., Whitehead K.A., Vegas A.J., Anderson D.G. Action and reaction: the biological response to siRNA and its delivery vehicles. Molecular Therapy 2012, 20(3):513-524.
54. Kaufmann J., Ahrens K., Santel A. RNA interference for therapy in the vascular endothelium. Microvascular Research 2010, 80(2):286-293.
55. Kim E.-M., Jeong H.-J., Park I.-K., Cho C.-S., Moon H.-B., Yu D.-Y., et al. Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly(ethylene glycol): invitro and invivo studies. Journal of Controlled Release 2005, 108(2-3):557-567.
56. Kumar V., Abbas A., Fausto N., Aster J. Pathologic basis of disease 2009, Robbins and Cotran. 8th ed.
57. Lee H., Lytton-Jean A.K.R., Chen Y., Love K.T., Park A.I., Karagiannis E.D., et al. Molecularly self-assembled nucleic acid nanoparticles for targeted invivo siRNA delivery. Nature Nanotechnology June 2012, 7:389-393.
58. Leung A.K.K., Hafez I.M., Baoukina S., Belliveau N.M., Zhigaltsev I.V., Afshinmanesh E., et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. The Journal of Physical Chemistry C 2012, 116:18440-18450.
59. Love K.T., Mahon K.P., Levins C.G., Whitehead K.a, Querbes W., Dorkin J.R., et al. Lipid-like materials for low-dose, invivo gene silencing. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(5):1864-1869.
60. Lu J., Li Z., Zink J.I., Tamanoi F. Invivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine: Nanotechnology, Biology, and Medicine 2012, 8(2):212-220.
61. Maier M.A., Jayaraman M., Matsuda S., Liu J., Barros S., Querbes W. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Molecular therapy: The Journal of the American Society of Gene Therapy 2013, 21(8):1570-1578.
62. Mamidyala S.K., Dutta S., Chrunyk B.a, Préville C., Wang H., Withka J.M., et al. Glycomimetic ligands for the human asialoglycoprotein receptor. Journal of the American Chemical Society 2012, 134(4):1978-1981.
63. Meier M., Bider M.D., Malashkevich V.N., Spiess M., Burkhard P. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. Journal of Molecular Biology 2000, 300(4):857-865.
64. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C. Requirement for NF-κB signaling in a mouse model of lung cancer. Nature 2009, 462(7269):104-107.
65. Monopoli M.P., Aberg C., Salvati A., Dawson K.a Biomolecular coronas provide the biological identity of nanosized materials. Nature Nanotechnology 2012, 7(12):779-786.
66. Nguyen D.X., Massagué J. Genetic determinants of cancer metastasis. Nature Reviews Genetics 2007, 8(5):341-352.
67. Nolan C.J., Damm P., Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378(9786):169-181.
68. Parmar R.G., Busuek M., Walsh E.S., Leander K.R., Howell B.J., Sepp-Lorenzino L., et al. Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the invivo systemic delivery of siRNA therapeutics. Bioconjugate Chemistry 2013, 24(4):640-647.
69. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology 2007, 7(10):803-815.
70. Rader D.J., Cohen J., Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. The Journal of Clinical Investigation 2003, 111(12):1795-1803.
71. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews Molecular Cell Biology 2007, 8(1):23-36.
72. Ren Y., Cheung H.W., von Maltzhan G., Agrawal A., Cowley G.S., Weir B.a, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Science Translational Medicine 2012, 4(147):1-12.
73. Rensen P.C., Sliedregt L.A., Ferns M., Kieviet E., van Rossenberg S.M., van Leeuwen S.H., et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes invitro and invivo. The Journal of Biological Chemistry 2001, 276(40):37577-37584.
74. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annual Review of Biochemistry 2012, 81:145-166.
75. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L., et al. Dynamic PolyConjugates for targeted invivo delivery of siRNA to hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(32):12982-12987.
76. Sabin L.R., Delás M.J., Hannon G.J. Dogma derailed: the many influences of RNA on the genome. Molecular Cell 2013, 49(5):783-794.
77. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology 2014, 32(4):347-355.
78. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Durieux B., et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Therapy 2006, 13(18):1360-1370.
79. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Therapy 2006, 13(16):1222-1234.
80. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nature Reviews Cancer 2012, 12(1):39-50.
81. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology 2010, 28(2):172-176.
82. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432(7014):173-178.
83. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 1990, 29(43).
84. Tenzer S., Docter D., Kuharev J., Musyanovych A., Fetz V., Hecht R., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nature Nanotechnology 2013, 8(10):772-781.
85. Tortorella S., Karagiannis T.C. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. The Journal of Membrane Biology 2014, 247(4):291-307.
86. Ulitsky I., Bartel D.P. lincRNAs: genomics, evolution, and mechanisms. Cell 2013, 154(1):26-46.
87. Wang J., Loberg R., Taichman R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Reviews 2006, 25(4):573-587.
88. Wang M., Alberti K., Varone A., Pouli D., Georgakoudi I., Xu Q. Enhanced intracellular siRNA delivery using bioreducible lipid-like nanoparticles. Advanced Healthcare Materials 2014, 3(9):1398-1403.
89. Weis W.I. Structural basis of galactose recognition by C-type animal lectins. Journal of Biological Chemistry 1996, 271(12):6679-6685.
90. Whitehead K.A., Dahlman J.E., Langer R.S., Anderson D.G. Silencing or stimulation? siRNA delivery and the immune system. Annual Review of Chemical and Biomolecular Engineering 2011, 2(1):77-96.
91. Whitehead K.A., Dorkin J.R., Vegas A.J., Chang P.H., Veiseh O., Matthews J., et al. Degradable lipid nanoparticles with predictable invivo siRNA delivery activity. Nature Communications 2014, 5:4277.
92. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nature Reviews Drug Discovery 2009, 8(2):129-138.
93. Whitehead K.a, Matthews J., Chang P.H., Niroui F., Dorkin J.R., Severgnini M., et al. Invitro-invivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano 2012, 6:6922-6929.
94. Wisse E., Jacobs F., Topal B., Frederik P., De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene therapy 2008, 15(17):1193-1199.
95. Wong S.C., Klein J.J., Hamilton H.L., Chu Q., Frey C.L., Trubetskoy V.S., et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs invivo. Nucleic Acid Therapeutics 2012, 22(6):380-390.
96. Wooddell C.I., Rozema D.B., Hossbach M., John M., Hamilton H.L., Chu Q., et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Molecular Therapy 2013, 21(5):973-985.
97. Xue W., Dahlman J.E., Tammela T., Khan O.F., et al. Small RNA combination therapy for lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(34):E3553-E3561.
98. Yamada T., Peng C.G., Matsuda S., Addepalli H., Jayaprakash K.N., Alam M.R., et al. Versatile site-specific conjugation of small molecules to siRNA using click chemistry. The Journal of Organic Chemistry 2011, 76(5):1198-1211.